Click back through the chain of responses and see who was posting baseless statements. I cannot answer every question about the company or speak for the leadership from their perspective as I am only a shareholder. Neither can I answer for everything everyone else chooses to post. I post full-context sources that anyone can evaluate for themselves.
We need to avoid defamatory rumors about the company and its leadership and acknowledge that the long-serving management team are shareholders too.
Market cap can rise rapidly, mani. Nobody is posting false information because forward-looking speculation is by definition unknown. We do have some known aspects of the market that we can consider—the PD1 market is valued in the tens of billions and the global immunotherapy market overall is projected to reach hundreds of billions. Nobody can pinpoint precisely how much of that expanding market NWBO might potentially capture, and an acquisition price would depend on a confluence of factors and circumstances of timing surrounding any such hypothetical deal.
As I often say, it is advisable to seek credible full-context sources such as clinical data, independent licensed physicians, peer-reviewed medical literature, and government regulators.
Mani, I'll certainly admit I've mentioned sky high market caps in the past, however I believe there were always conditioned on certain things. Namely success not in just GBM, but in many cancers. In the highest extremes I suggested that this could be true for both DCVax-L and Direct.
I'd like to know if anyone here doesn't believe a market cap in excess of $100 billion isn't possible if the DCVax's become a part of the SOC in treating many different forms of solid cancer.
Market Data 
Markets 
AI
